对“帕博西尼联合内分泌治疗激素受体阳性、her2阴性转移性乳腺癌的有效性和安全性:现实世界结果”的更正。

IF 0.6 Q4 PHARMACOLOGY & PHARMACY

CANADIAN JOURNAL OF HOSPITAL PHARMACY Pub Date : 2022-04-04 DOI:10.4212/cjhp.v75i2.3285

引用次数: 0

摘要

[这更正了第75卷第26页的文章，PMID:34987260]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to "Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results".

[This corrects the article on p. 26 in vol. 75, PMID: 34987260.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

CANADIAN JOURNAL OF HOSPITAL PHARMACY PHARMACOLOGY & PHARMACY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： The CJHP is an academic journal that focuses on how pharmacists in hospitals and other collaborative health care settings optimize safe and effective drug use for patients in Canada and throughout the world. The aim of the CJHP is to be a respected international publication serving as a major venue for dissemination of information related to patient-centred pharmacy practice in hospitals and other collaborative health care settings in Canada and throughout the world.